X0306 4 2015-04-30 0 0000816284 CELGENE CORP /DE/ CELG 0001405288 FOUSE JACQUALYN A C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 0 1 0 0 see remarks Common Stock 2015-04-30 4 M 0 11200 0.00 A 59403 D Common Stock 2015-04-30 4 F 0 5292 108.06 D 54111 D Common Stock 1313 I 401(k) Plan Restricted Stock Unit 2015-04-30 4 M 0 11200 0.00 D Common Stock 11200 0 D Stock Option (right to buy) 109.90 2015-05-04 4 A 0 8625 0.00 A 2025-05-04 Common Stock 8625 8625 D Restricted Stock Unit 2015-05-04 4 A 0 3500 0.00 A 2018-05-04 Common Stock 3500 3500 D All of the restricted stock units granted to the reporting person on April 30, 2012 vested and settled for shares of the Company's common stock. The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 17, 2013). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Option is immediately exercisable and will vest in four equal annual installments commencing on May 4, 2016. The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 17, 2013). The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013) and vest on May 4, 2018. Vested shares will be delivered to the reporting person on the vesting date. President Hematology and Oncology /s/ Robert J. Hugin _____________________ Robert J. Hugin, Attorney-in-Fact 2015-05-04